Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Drospirenone is a synthetic progestin used primarily as an oral contraceptive to prevent pregnancy. It is available both as a progestin-only pill (notably under the brand name Slynd) and in combination with estrogens such as ethinyl estradiol or estetrol (as in Yaz and Yasmin) for combined oral contraception. In addition to its contraceptive use, drospirenone-containing products are approved for the treatment of moderate acne vulgaris and premenstrual dysphoric disorder (PMDD), and are also used in menopausal hormone therapy to treat vasomotor symptoms, vaginal atrophy, and help prevent postmenopausal osteoporosis[2][3][5]. Drospirenone acts as an agonist at the progesterone receptor, an antagonist at mineralocorticoid receptors (anti-mineralocorticoid activity), and an antagonist at androgen receptors (antiandrogenic activity)[2][6]. Its anti-mineralocorticoid effect opposes estrogen-induced water retention; its antiandrogenic effect helps reduce acne[2][6]. Drospirenone is structurally related to spironolactone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on drospirenone.